iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need. We believe our approach has the potential to replace and restore the function of a dysfunctional gene by knocking-in a healthy copy, regardless of mutation, to offer durable gene expression and long-term, potentially curative, therapeutic benefit.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/30/22	$65,000,000	Series A-1	LYFE Capital Novo Holdings OrbiMed Advisors Versant Ventures	undisclosed